Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing
Rhea-AI Summary
Anixa Biosciences (NASDAQ: ANIX) reported positive final Phase 1 results for its α-lactalbumin breast cancer vaccine and has engaged Cytovance Biologics to produce cGMP clinical material for a planned Phase 2 trial.
The Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of participants.
Positive
- 74% immune response rate in Phase 1 participants
- Phase 1 met primary endpoints with safety and tolerability at MTD
- Cytovance agreement for cGMP clinical material to support planned Phase 2
- Advancing to Phase 2 preparations following final Phase 1 data
Negative
- None.
News Market Reaction – ANIX
On the day this news was published, ANIX gained 5.43%, reflecting a notable positive market reaction. Argus tracked a peak move of +14.4% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $5M to the company's valuation, bringing the market cap to $94.55M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ANIX gained 3.2% while the only peer in the momentum scan, ADAG, moved down about 3.32%, indicating a stock-specific reaction rather than a sector-wide biotech move.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Ovarian CAR-T update | Positive | -2.0% | Conference presentation update on Phase 1 ovarian cancer CAR-T trial design and status. |
| Dec 11 | Breast vaccine data | Positive | -25.4% | Positive Phase 1 breast cancer vaccine data with 74% immune responses presented at SABCS. |
| Oct 07 | Trial visit completion | Positive | +26.5% | Completion of final patient visit in Phase 1 breast cancer vaccine trial with >70% responses. |
| Sep 08 | CAR-T dosing escalation | Positive | +0.3% | Completion of fourth cohort dosing in ovarian CAR-T trial with higher cell dose and no DLTs. |
| Aug 18 | CAR-T cohort progress | Positive | +0.3% | Second patient treated in fourth cohort of ovarian cancer CAR-T trial at higher cell dose. |
Clinical trial news has produced mixed reactions: smaller operational updates often aligned positively, while major breast cancer vaccine data once saw a sharp downside move.
Over the last several clinical updates, Anixa highlighted progress across its breast cancer vaccine and ovarian cancer CAR-T programs, including patient dosing escalations, survival outliers, and completion of key Phase 1 milestones. Notably, final Phase 1 breast cancer vaccine data showing immune responses in 74% of participants led to a -25.42% move on Dec 11, 2025, while earlier enrollment and visit-completion news on Oct 7, 2025 saw a 26.46% gain. Today’s Phase 2 preparation and manufacturing agreement continue that development arc.
Historical Comparison
In the past 5 clinical-trial releases, ANIX’s average move was about -0.05%, with both sharp upside and downside around breast cancer vaccine milestones. Today’s Phase 2 prep fits this ongoing development cycle.
Clinical updates show progression from early ovarian CAR-T dosing cohorts and completion of Phase 1 breast vaccine visits to full Phase 1 data at SABCS and now operational steps toward a Phase 2 breast cancer vaccine trial.
Regulatory & Risk Context
Anixa has an effective Form S-3 shelf registration dated Sep 10, 2025, allowing it to offer various securities including common and preferred stock, warrants, subscription rights, depositary shares and units. The filing details estimated offering expenses totaling $96,146, but investors should note that actual usage and amounts would depend on future capital-raising decisions.
Market Pulse Summary
The stock moved +5.4% in the session following this news. A strong positive reaction aligns with the clearly favorable Phase 1 data, including protocol-defined immune responses in 74% of participants and a clean safety profile at the maximum tolerated dose. Historically, ANIX’s clinical updates have produced both rallies and sharp drops, so investors watching a big gain may consider that prior breast vaccine data on Dec 11, 2025 coincided with a -25.42% move, highlighting potential volatility as the program advances.
Key Terms
cGMP technical
cdmo technical
α-lactalbumin medical
maximum tolerated dose medical
immunotherapy medical
AI-generated analysis. Not financial advice.
Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, and generated protocol-defined immune responses in
The agreement follows positive final Phase 1 results in which the investigational vaccine met all primary endpoints, was safe and well tolerated at the maximum tolerated dose, and generated protocol-defined immune responses in
Anixa's breast cancer vaccine, developed in collaboration with Cleveland Clinic, targets α-lactalbumin—a lactation-associated protein that is typically expressed only in breast tissue during lactation, but which re-emerges in many forms of breast cancer. By generating an immune response against α-lactalbumin-expressing cells, the vaccine is designed to potentially provide both therapeutic and preventive benefits for patients with tumors expressing this protein. The vaccine is based on preclinical research led by the late Vincent Tuohy, Ph.D., who served as the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research at Cleveland Clinic.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, commented, "With final Phase 1 data demonstrating safety, tolerability, and strong immune responses in
"We are pleased to partner with Anixa to manufacture clinical materials for its Phase 2 breast cancer vaccine trial," said Ping Zhang, CEO of Cytovance Biologics. "Our team is committed to delivering high-quality cGMP manufacturing solutions that support innovative biotech programs. We look forward to leveraging our development and production capabilities to help advance this promising immunotherapy candidate."
About Cytovance
Cytovance Biologics is an established CDMO specializing in the expression and production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. For 20 years, Cytovance has offered flexibility and ingenuity across a full range of integrated services, supporting clients on their journey from molecule to commercial manufacturing. Learn more about Cytovance Biologics at www.cytovance.com.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Anixa Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
Cytovance Media Contact:
Emily Steinhauer
esteinhauer@cglife.com
203-218-9906
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-advances-breast-cancer-vaccine-toward-phase-2-after-positive-phase-1-results-cytovance-selected-for-cgmp-manufacturing-302730803.html
SOURCE Anixa Biosciences, Inc.
FAQ
What did Anixa (ANIX) announce on April 1, 2026 about its breast cancer vaccine?
How will the Cytovance agreement affect Anixa (ANIX) Phase 2 plans?
What clinical result metric did Anixa (ANIX) report from Phase 1 on April 1, 2026?
Does the April 1, 2026 announcement confirm a Phase 2 trial start date for Anixa (ANIX)?
What is the vaccine target described by Anixa (ANIX) in the April 1, 2026 release?
